Lamivudine/Zidovudine Viatris

Lamivudine and Zidovudine, the active ingredients in Lamivudine/Zidovudine Viatris, are nucleoside reverse transcriptase inhibitors presented as an oral tablet for systemic use. They are indicated for the treatment of HIV‑1 infection in adults and pediatric patients, where they work synergistically to inhibit viral replication, improve immune function, and slow disease progression.

GNH USA supplies Lamivudine/Zidovudine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory conformity and reliable global distribution.

Lamivudine/Zidovudine is used in antiretroviral therapy to target HIV replication.

- HIV‑1 infection: reduces viral load and helps restore CD4+ T‑cell counts. - Chronic HIV infection: maintains virologic suppression and slows disease progression. - Treatment‑experienced patients: provides an alternative regimen when resistance to other NRTIs develops.

Lamivudine/Zidovudine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Headache: transient cranial pain. - Fatigue: generalised tiredness. - Anemia: reduced red blood cell count. - Diarrhoea: loose stools. - Neutropenia: lowered neutrophil levels.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance. - Hepatic steatosis: fatty liver disease. - Bone marrow suppression: pancytopenia risk. - Hypersensitivity reactions: rash, fever, organ involvement. - Pancreatitis: inflammation of the pancreas. - Severe anemia: requiring transfusion.

When prescribing Lamivudine/Zidovudine, clinicians should observe several safety considerations.

- Monitor blood counts: watch for anemia and neutropenia. - Assess liver function: detect hepatic steatosis or elevated enzymes. - Evaluate renal function: adjust use in severe impairment. - Counsel on adherence: maintain consistent dosing to prevent resistance. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lamivudine/Zidovudine can interact with other medicines, affecting efficacy or toxicity.

Major Interactions (Avoid): - Didanosine: increased risk of peripheral neuropathy and pancreatitis. - Stavudine: heightened mitochondrial toxicity. - Myelosuppressive agents: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Rifampin: may lower plasma concentrations of the NRTIs. - Antacids containing aluminium or magnesium: can reduce absorption. - Protease inhibitors: may alter drug levels requiring dose adjustment.